Moderna (NASDAQ:MRNA) +3.5% after-hours as results from a Phase 1 study shows its mRNA-1273 coronavirus vaccine candidate is well-tolerated and generates a strong immune response in older adults.
The vaccine, which is co-developed by researchers at Moderna and the National Institute of Allergy and Infectious Diseases, produced virus neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly equal to high-dose flu shots, according to a study published in the New England Journal of Medicine.
The findings are reassuring because immunity tends to weaken with age, Dr. Evan Anderson, one of the study's lead researchers from Emory University, tells Reuters.
Swiss contract manufacturer Lonza said today it is confident that its plants in the U.S. and Switzerland will be ready to produce commercial quantities of mRNA-1273, expected to total 300M doses annually.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.